Medical Articles: Diagnosis, Risks, Research

  • Despite Poor Prognosis, New Treatment Options for Mesothelioma May Extend Life and Decrease Symptoms (11/15/05)

Gene Identifiers

Blood Tests to Diagnose Mesothelioma

Asbestos Epidemic, Epidemiology, Risks/Dangers

  • WA Team's Mesothelioma Breakthrough (12/18/03)
  • First-ever Blood Test for Mesothelioma Being Developed (11/14/03)
  • Australians Prepare for mesothelioma Epidemic with Breakthrough Diagnostic Test (9/16/03)
  • Barriers to Treatment Can be Both Physical and Financial: CNN Lou Dobbs Moneyline (2/6/03)
  • Drug Sales Bring Huge Profits, and Scrutiny, to Cancer Doctors (1/27/03)
  • Asbestos-Linked Cancers Show Unexpected Decline in Sweden (12/3/02)
  • Coping with Cancer During the Holidays, ASCO Chat Line (coping with emotional issues, strategies for managing symptoms, techniques for dealing with stress, and how to take care of yourself) (12/2/02)
  • MARF Doctor Hails Alimta as "A New Standard Therapy" for Treating Mesothelioma; Lilly Makes Drug Available through Expanded Access Program. Indianapolis, Indiana, November 14, 2002 (11/20/02)
  • Important Studies Relating To Asbestos Fiber Size
    • Asbestos tissue burden study on human malignant mesothelioma
    • Asbestos fibers contributing to the induction of human malignant mesothelioma
  • Unresectable Mesothelioma: A New Standard of Care (5/29/02)
  • Spirituality Makes People Feel Better (5/13/02)
  • Understanding and Preventing Post Surgery Pain for Mesothelioma Patients: An Outline (5/8/02)
  • Checklist of Questions for Your Doctor. (4/26/02)
  • No Doubt About it! Medical/Scientific Literature Overwhelmingly Proves that Canadian Chrysotile Asbestos Used in the US Causes Malignant Mesothelioma in Americans. (3/21/02)
  • World Mesothelioma Epidemic Approaching Fast (3/14/02)
  • Seminars in Oncology - "...current, authoritative, and practical reviews of developments in the diagnosis and management of patients with cancer. " (2/13/02)
    • Mesothelioma: Are we making progress?
    • The pathogenesis of mesothelioma
    • The epidemiology of mesothelioma
    • The role of imaging in malignant pleural mesothelioma
    • Prognostic factors in mesothelioma
    • Multimodality treatment of diffuse malignant pleural mesothelioma
    • Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience
    • Chemotherapy for malignant mesothelioma: From doxorubicin to vinorelbine
    • The role of gemcitabine in the treatment of malignant mesothelioma
    • The emerging role of antifolates in the treatment of malignant pleural mesothelioma
    • New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents
    • Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council

Medical Abstracts (1999-2002)

  • Well-Differentiated Papillary Mesothelioma (6/12/02)
  • Summary of Medical Articles Concerning Treatment Options for Mesothelioma Patients. Source - MEDLINE
    • Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology (10/14/02)
    • Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies (10/14/02)
    • A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma (10/14/02)
    • Treatment of malignant pleural mesothelioma (6/2001)
    • Trimodality management of malignant pleural mesothelioma (3/2001)
    • Treatment of malignant mesothelioma (2/2001)
    • Malignant pleural mesothelioma (2001)
    • Mesothelioma of the pleura and peritoneum. Diagnostic and therapeutic sequelae (8/2000)
    • Mesothelioma--VATS biopsy and lung mobilization improves diagnosis and palliatio (12/1999)
    • Contemporary management of malignant pleural mesothelioma (1999)
    • Pleuropneumonectomy in the treatment of malignant pleural mesothelioma (12/1999)
    • Surgical treatment of mesotheliomapleurectomy (12/1999)
    • Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically (11/1999)
  • Diagnostic Value of CYFRA 21­1 Tumor Marker and CEA in Pleural Effusion Due to Mesothelioma (5/31/01)
  • Blocking VEFG May Prevent Tumor Spread (2/1/01)
  • Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma Shows Improvement in Survival and Quality of Life (12/8/00 )
  • Combined Epirubicin and Interleukin-2 Regimen in the Treatment of MM: A Multicenter Phase II Study of the Italian Group on Rare Tumors (8/29/00)
  • Induction Chemotherapy, Extrapleural Pneumonectomy And Adjuvant Fast Neutron Radiationtherapy For Pleural Mesothelioma (Dmm) (5/12/00)
  • A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies (response noted for Mesothelioma Patient). (3/27/00)
  • Talc Induces Apoptosis in Human Malignant Mesothelioma Cells In Vitro (2/22/00)
  • Management of Peritoneal-Surface Malignancy: The Surgeon's Role (2/22/00)
  • Australia Doctors: Gene Therapy (IL-12) Retards Mesothelioma in Mice But Causes Side Effects (9/27/99)
  • Clinical Picture, Response to Therapy, and Survival of Women with Diffuse Malignant Peritoneal Mesothelioma, January 1999

Medical Abstracts (1994-1998)

Simian Virus (SV40)

  • No Proof Polio Vaccine Later Caused Cancer (10/23/02)
  • Legal Documents Raise Question of Whether Polio Vaccines Remained Tainted With SV40 After 1961, HarrisMartin Reports. (12/13/00)
  • SV40, Asbestos, and Mesothelioma - Where Are We Going? (11/7/00)
  • SV40 Sequences in Mesothelioma Predict Poorer Survival (10/2/00)
  • SV40: Potential Vaccine for Mesothelioma? (3/4/99)

MEDLINE - Medicine On Line

Intensity Modulated Radiation Therapy (IMRT)

Gemzar/Gemcitabene

  • Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-celllung cancer. Southern Italy Cooperative Oncology Group.
  • Gemcitabine/alimta in locally advanced or metastatic non-small-cell lung cancer.
  • Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
  • Gemcitabine/carboplatin combination regimens: importance of dose schedule.
  • Combination chemoradiotherapy with gemcitabine: potential applications.
  • Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
  • Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
  • Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
  • Gemcitabine/cisplatin as induction therapy for stage IIIA N2 non-small-cell lung cancer. )
  • 66 Year Old MM "Still Here" After 44 Months, Praises MD Anderson. Missouri City, TX (3/7/00)
  • 43 Year Old Woman Has High Hopes for Lovastatin - Cleveland, OH (2/24/00)
  • Lovastatin-Induced Proliferation Inhibition and Apoptosis in C6 Glial Cells1 (2/22/00)
  • 55 Year Old MM Patient Receiving Lovastatin (9/30/99)
  • Lovastatin Induces Apoptosis in Mesothelioma Cells: Rubins JB, May 22, 1998
  • Cholesterol Drug May Help Treat Mesothelioma, But More Research Needed

PET Scans

  • Talc Pleurodesis Simulating Pleural Metastases on FDG PET Imaging (5/14/02)
  • PET Scans Valuable Diagnostic Tool (4/30/01)
  • PET Scans More Accurate at Detecting Lung Cancer than Standard Methods (7/27/00)

* * * * * * * * * * *
Neither the Law Offices of Roger G. Worthington nor its clients herein (including clients of other law firms) intend to waive the attorney-client privilege by posting information about these clients herein. The information contained herein is intended to educate and inform asbestos cancer patients and their families of potential medical and legal options. Roger Worthington is not a medical doctor. Patients are advised to consult with a medical doctor and/or an attorney if they have questions regarding this information. The opinions expressed herein by persons other than Roger Worthington are not necessarily endorsed by the Law Offices of Roger G. Worthington, P.C. This is an open forum.

* * * * * * * * * * *